International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
Pertti Panula(University of Helsinki), Helmut L. Haas(Research Center Borstel - Leibniz Lung Center), Paul L. Chazot(University of Helsinki), Wai L. S. Liu(University of Helsinki), Robin L. Thurmond(Janssen (United States)), Rob Leurs(Vrije Universiteit Amsterdam), Holger Stark(Heinrich Heine University Düsseldorf), Marlon Cowart(University of Helsinki), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 558
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
Orexin/Hypocretin Excites the Histaminergic Neurons of the Tuberomammillary Nucleus
|Journal of Neuroscience|2001|500